-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SS2sVaMn9SM/Dyx4N8lzqc7JQ7Cnz2ZnawFalDdvncUebdDYaVlWjco4VpLeJ3Cj sduYyL4VHGGGaZGrV4A0fg== 0001104659-07-038163.txt : 20070510 0001104659-07-038163.hdr.sgml : 20070510 20070510142930 ACCESSION NUMBER: 0001104659-07-038163 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20070510 DATE AS OF CHANGE: 20070510 EFFECTIVENESS DATE: 20070510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 000-14680 FILM NUMBER: 07836856 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQ CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 DEFA14A 1 a07-13164_2defa14a.htm DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.     )

 

Filed by the Registrant  x

 

Filed by a Party other than the Registrant  o

 

Check the appropriate box:

o

Preliminary Proxy Statement

o

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o

Definitive Proxy Statement

x

Definitive Additional Materials

o

Soliciting Material Pursuant to §240.14a-12

 

Genzyme Corporation

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

x

No fee required.

o

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1)

Title of each class of securities to which transaction applies:

 

 

 

 

(2)

Aggregate number of securities to which transaction applies:

 

 

 

 

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

 

 

(4)

Proposed maximum aggregate value of transaction:

 

 

 

 

(5)

Total fee paid:

 

 

 

o

Fee paid previously with preliminary materials.

o

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)

Amount Previously Paid:

 

 

 

 

(2)

Form, Schedule or Registration Statement No.:

 

 

 

 

(3)

Filing Party:

 

 

 

 

(4)

Date Filed:

 

 

 

 




 

 

GENZYME CORPORATION
500 Kendall Street
Cambridge, MA 02142
(617) 252-7500

 

May 10, 2007

Genzyme Shareholders:

The May 24, 2007 Annual Meeting of Shareholders is just a couple of weeks away.  This is a reminder to you that if you have not yet voted your proxy, please do so as soon as possible.  Your vote is important to us, and we want to be sure it is received in time to be counted.

Annual Meeting Information

Genzyme’s Annual Meeting of Shareholders will be held at 2 p.m. ET on Thursday, May 24, 2007 at the Cambridge Marriott Hotel, 2 Cambridge Center, Cambridge, Massachusetts.

Proposals/Vote Recommendation

We are requesting your support in voting FOR the following six company-sponsored proposals:

·                  The re-election of two directors for one-year terms;

·                  Amendments to our 2004 Equity Incentive Plan;

·                  Approval of a new Director Equity Incentive Plan;

·                  An amendment to our 1999 Employee Stock Purchase Plan;

·                  A by-law amendment to provide for majority voting for the election of directors in uncontested elections; and

·                  Ratification of our selection of independent auditors for 2007.

In addition, we are asking for your support in voting AGAINST a shareholder-sponsored proposal that executive severance agreements be approved by shareholders.

For more detailed information about each proposal, voting instructions, or the annual meeting, please refer to the proxy statement that has previously been delivered to you.  If you have not yet voted, please do so TODAY by telephone, by the Internet, or by signing and returning the enclosed voting form in the postage-paid envelope provided.  Whatever method you choose, we thank you for participating in this year’s proxy process.

If you have any questions about, or need assistance with, voting your proxy, please contact our proxy solicitor, Innisfree M&A Incorporated at (888) 750-5834 or the Genzyme Shareholder Relations group at (617) 768-6686.



GRAPHIC 2 g131642cai001.jpg GRAPHIC begin 644 g131642cai001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V-W2*-I)& M5$4$LS'``'4DUPVL>/)WD>'2D6.,'`N'&6;IR%/`[]<\'M3O'VJR&>+2XI,1 MA1),%;[Q)X!';&,_B/058\(>%TBCBU6^57D8![>/J$!Y#'W]/3Z]/*K5JM:K M["CI;=GBXC$5J]=X?#NUMVE>K5%<6MO=QB.Y@BG0'(61`P!]<&D\NDO>C4= MR7E,E[T*KYNYR5OXVCOM)NH+G_1;WR)3')&<(3M.W!SD-_AUR<56\#ZC?7>M M31W-Y<3H+=B%DE9@#N7G!-4/%WA]='NDGM4Q:3<*HW'RV`&02<]>HY]?2J>@ M:D=*>^ND91+]D*19('S%T`(SUQR<>U<;KU85XQK/X?Q.!XFM#$QC7?P_BCMO M$7BN#16^S0HMQ=D9*YPL?'!;]./3TXSR$_B#Q!K5SBWDN`5&1%9AA@<`GCD_ MB3UJ+0-&E\0ZHRRRN(U_>3RG))R>F?[Q]_<\XQ7I=CI]KIML+>SA6*($G`). M2>Y)Y-=$%7QK23UKT.N8\2>$8-1CDN[!%BO22[+G" MS>H]`??USGKD.6"K4%S4)?(QW'AVZO+.??K]*H:7K,^GV]W:% MF:VNH71H\9PQ4@,/3G&?;Z"JNGV;ZAJ$%HFX&:0+E5W;1W./89/X5RUL9*K* M$H:/MYG%7Q\ZTZDMK>9J3^(/$&M7.+>2X!49$5F&&!P">.3^)/6J:0:WI M44DJ17]G&<;W"O&/;)X]?UKT_3=*L])MA!:0JG`#/CYGQW8]^I_I5RNS^SIS M7-.;YCO655)KFJ5'S'G^A>-KFWECM]4;SK?[OG8^=.@!./O#U[\]3TIWB%]> MEUN>336U%[1@AB:W+F,@HO(*\=?2I_&?ANWM[;^U+&)8@I"S1(`%P>`P';G` MP.N<^N;'@'5?.M9=+D/S09DB_P!PGD=.Q/<_Q>U8I5'/ZM6EYI_U_5S!1K.I M]3KS?=/]/ZZG._\`%6?]1C_R+2._BF*-I)&U=$4$LS&4``=237J5<;XV\0>6 MK:1:NZR''VAQP-I&=GOG()_+G)JJ^$C1IN<:G@/4/LVKR617*W:\$#D,H)'?IC=^.*Y\%5J M4ZT>>]I'-E]:K2KQ]I>TN_X?B>AT45F>(=2.E:+<72,HEQLBR0/F/`(SUQR< M>U?0SFH1GS22M<2W1:/:JW$K,JG(.<9]`1^-9UO9O<6MW<#<$MHU8G;D$EU4# M/;J3^!JUX>TT:KK5O:NK&+.^7`)^4G:B.\U[0_*'F7EHHSY:2A@A M]<*W!Z^G>O541(HUCC5410`JJ,``=`!3+FV@O+9[:YC62*0896[UZCRZ7Q>T M?-W/9>4S^)57S=_ZU.?T#QC;:C$T>H20VEPG.2VU''L2>#[9]_7'.ZKXVU&\ ME=+)OLEORJX`WL#W)['Z8QGJ>M9&LZ?_`&5J]Q9!MRQ-\ISD[2,C/`YP1GWK MLO!&BVT5A'JS#S+B;<$)'$8!*\>YQU_#USSPJXG$2]A>S6[.6G6Q>*E]6YK- M7N^NG]?,Y3[%XA^U?:_LNI?:/^>WER;^F.O7IQ6AI7C#4],G%OJ!>XA5MLBR MC]ZG)S@GG.3T/ICBO1ZY?QEX?BO+.74X$VW4"[GQC$B#KGW`YS[8YXQM/!5* M$74I3=T=%3+ZN&BZM";NM;=SH[:Y@O+9+FVD62*095E[UE^(O$4&AVV!MDNY M!^ZB]/\`:;V_G^9'%^&O$3:)%>HQW*\6Z)""1YO`'?`&#S_NBHM*TR\\5:K, MTUPP.-\T[+NQV`QT^@XX!],4Y9A*I3C&DO??X#EF2Q2*U!7WQA>3@#OFH+?3M>M)#);6>HP.1@M'$ZDCTR!7I>EZ/9:/`8 MK.+;NQO1KW M?Y7QC`&X?GD@D\UWVGWT&I6,5Y;EC%*,C<,$%[768WFC58;W M`VR\X;'0,/Z]>GIBN/\`#6M7.BZHMK*=MO+*$FCE.T1G."W/0CO].>Q!"K5P MM10K.\7LPA6KX*JJ=>7-![/^OZ['IM%%%>N>Z>5ZFDFI^+YX)9<-+>>2'V_= M&[:..^`!7JE>3:ZD]GXDO22T4HN&D4JW(R=RD$>Q!KU#3[Q-0T^"[3:!-&&P MK;MI[C/L_^9X6527M:L7\5_P#,LT445ZY[IC>++$7WAVY& M%WP#SD+$C&WKT_V=P_&O+:]-\:S1Q>&9T=L-*R(@QU.X-_)37F:H[JS*K,$& M6('W1D#)_$@?C7SN:6]LK=CY3.;?6%;>W^9J:-XBNM"CE6U@MV,Q!=I`Q/'0 M<$#N?SK3_P"%@:M_S[V?_?#_`/Q57_`UKIM[IMPEQ:V\\\S_[X?\`^*H_X6!JW_/O9_\`?#__`!5=K_8FD_\`0+L__`=/\*/[$TG_`*!= MG_X#I_A71]6Q?_/TZ?J>._Y_'E%[=->WDMTT:1M,Q=E3.,GKU)/7FM3P=_R- M-G_P/_T!JZ+5-1\)?8+R&W2S^T>4ZQF.U_CP0,,%QU[YKG?!W_(TV?\`P/\` M]`:O,5)4\1#WE*[6WJ>0J*I8JG[ZE=K;U/4:***^G/L3+\36WVKPY?1[]FV( MR9QG[OS8_'&*Y#X?_P#(=G_Z]6_]"6NUUO\`Y`6H?]>LG_H)KAO`TT=MJUU/ M*VV.*S=W;&<`,I->3BK+%TV>)C$ECJ4CL_$&M1Z)IK3Y1IW^6&-C]X]SQV'4 M_EGFO.-)TNYU_5/(63YFS)+*YR0,\MZDY/YG\:EUW5Y_$&J[XUE,6=EO#U([ M=!W)^O8@>'=#30M/\DLLD\AW2N!W]!WP/?U)XSBL7?'5_P"Y'^OQ_(YW M?,<3;_EW'^OQ_(OPV5M;V:V<4"+;JNSR\9!'?.>N>^>M>5WD,FA>('1%^:TG M#QB0YR`=RYQZC%>MUQ?Q`TQW6#5(]S!!Y,H_NC)*GIZD@Y/<5TYC1O24X[Q_ M(Z\UH/M2$U]#IT;-BW&^3DX+ M,!@8]AW_`-HU?\%ZLL?A^\2;>RV&9,!1]P@M@>IR&Z^HKE[.*7Q)XC1;A\-= M2EI"">%')`SGH!@?A6&*Q+JT(1CO/^OS.?&XMUL-3A#>?]?F;PTY;'X<3RLF MV:ZV2N3@G&]=O([8P<>I-5?A_P#\AV?_`*]6_P#0EKJ/&/\`R*UY_P``_P#0 MUKE_A_\`\AV?_KU;_P!"6IJ4U3Q=*"Z)?J15I*ECJ--=$OS9Z'1117N'T9YY M\0/^0[!_UZK_`.A-74>#O^16L_\`@?\`Z&UJ_\`H35U'@[_ M`)%:S_X'_P"AM7CX;_?JGI_D>#A/^1E5]'^:-NJ.M_\`("U#_KUD_P#035ZJ M.M_\@+4/^O63_P!!->K4^!^A[57^'+T9Y%6KHWB*ZT*.5;6"W8S$%VD#$\=! MP0.Y_.LJNO\``JV%Y]JL[NTMII%Q+&9(0S$=&Y/8?+Q[FOE,+&4JJ479]SXK M!QG*NHPERON0?\+`U;_GWL_^^'_^*H_X6!JW_/O9_P#?#_\`Q5=K_8FD_P#0 M+L__``'3_"C^Q-)_Z!=G_P"`Z?X5[7U;%_\`/T]_ZGCO^?QQ7_"P-6_Y][/_ M`+X?_P"*KG]0O7U&^ENY(HHWE.66)<+G')Q[]3[FO5?[$TG_`*!=G_X#I_A6 M1_:'@XS^0L%F\F[8%CLBVXYQQA>?PK"MA:K256JOF<^(P5:22K5E;I2 MOZ\>OISGL=6\566C7GV6ZM[DL5#JR*I#`_\``L]01^%5;W0M,\6VL6J6TCV\ MLJ\2!.N#C#+W(P1D'\P!7DUJ5ZSGAY>^MT>)7H0"5;^&+/5)G",#CI@_7J,BH[_Q5H]A$'-XEPQZ);L')Z>AP.OYDZGJ.H>);Z2;RV*0QLZQ*?EB0#).?YGN<#T%6?"5A'J=Y>V4IPLM MFP#?W3O0@^^"`:Z;6+:Q\,^%KJ.SC5'N0(=SY9I"1@Y/^[N/89[O7H".>GL*Z"[L MK:_@,%W`DT9_A<9P<8R/0\GDB^C_`*_(ZB;Q!H\$32OJ=L57J$D#G\ADFN5UGQV; MFV:WTN*6#>,--(0&7U"@9QVYSZ_6J%MX&UJ?=YB0V^W&/-D!W?3;G]:Z/0O! M<&EW*7=W,MS,H!10F%C;N??V/'KC.,#J8RO[JCRKN)U,?B?=4>1/=_\`#ZF' MI'AJY@TR]U2]5X#':S"*)AAB2C`E@>@Y..YZ].M'P=_R--G_`,#_`/0&KTJ] MMOMEA<6N_9YT31[L9QD$9Q^-<]HW@O\`LG58;[^T/-\K=\GD['FF$KUYQ=)7LNZ,WPE<:+I\[7^HW;1W*$K%'Y; M$`$6UOKFC/"'S#=1!D?!XSRK8X/7!Q7+_`/"NO^HK_P"2_P#]E77V5M]C ML+>UW[_)B6/=C&<`#./PKMHO$5+QKQ27]>;/1P\L54YHXF"2MT_X=GD&^>V, M\!#1EQYG*C\J[7X?Z:$MI]2=6#R'RH\@CY1@DCUR<#VVUR^K2I MJ_B*9[&)0+B8+$J\;SP`><8W'GGUKU#3[--/T^"T3:1#&%RJ[=Q[G'NWRMV<$G.VWVRPN+7?L\Z)H]V,XR",X_&N^:;BTCTZB;@T MNQY?X;M(K_78+2<9CE613P,CY&Y&>XZCWI][87_A768I,Y*-OAE&0L@'4TSQY8W$>W44:UE`Y9071N MG3'([\>W6MG_`(2#1_(\[^T[;;MW8\P;L8S]WKGVQFN9OOAZX8MI]ZI!(PEP M,8&.?F'7GV%9D7@;6I)WC9(8E7.)7D&UN>V,GWY`K15\;3]V4+^?_#&JQ.8T MO=G3YO/_`(;_`(!IZWXZ2:":UTR.5=PVBY+;2.><#'<=^#SVQ3?!OAJ1I8M7 MO%VHOS01L.7/9CGH.X[YY],W](\"VMG()M0D6[?`(CVD(K=3W^;\<#KD>G55 MI1PU6K-5<1TV1M0PE:M45;%=-EV_K_APHHHKU#V#"\5Z$^M:>OV?;]IMR6C# M'&X'JOH,X')].V:XK0_$%YX=N9(S&TD1)$MNYVX8<9Z<'UX_ICU*LS5_#^GZ MTH-U&PE4866,X8#.<>A_$'J:\_$X24I^UI.TOS/+Q>!G.I[>@[37XE>S\7Z+ M>;%^U>0[Y^2=2N,>K?=[>M,N_&FBVN0L[W#*VTK"A/XY.`1]#62_PZ0R,8]4 M94R=H:#)`[9.X9_*A/AT@D4R:HS)D;@L&"1WP=QQ^59^TQ]K@_4UWGAW0TT+3_`"2R MR3R'=*X'?T'?`]_4GC.*?IOA[2]*8/:VJ^:`!YKG@>F%%%%`!1110`4444`%%%%`!1110`5C>*]3 M?2]"EDBW"68^3&P_A)!R^*V:P?$/AJ37YX7-_Y$<*D+'Y.[DGDYR/ M0?E6&(]I[)JFKLYL5[3V,E25Y,YCP+IB7FJO=R[2EF`0I[NBU MG:'I$>B::+1'\QMQ=Y,8W$^V3C@`?A6C6>#H>QI*+WZF6`PWU>@HO?=A1117 A6=P4444`%%%%`!1110`4444`%%%%`!1110`4444`?__9 ` end
-----END PRIVACY-ENHANCED MESSAGE-----